SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 226.8

Change

+1.45 (+0.64)%

Market Cap

USD 0.66B

Volume

465.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.01 (-0.02%)

USD 420.85B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.08%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.09%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.02 (-0.07%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.09 (+0.35%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.29%)

USD 102.32B
8R80:XETRA Amundi Index Solutions - Amund..

+0.18 (+0.13%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.06 (-0.12%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.50 (-0.50%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.84 (-0.32%)

USD 80.38B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.72% 82% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.72% 82% B 79% B-
Trailing 12 Months  
Capital Gain 10.15% 46% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.15% 46% F 49% F
Trailing 5 Years  
Capital Gain 70.14% 80% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.14% 80% B- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.38% 70% C- 68% D+
Dividend Return 8.38% 69% C- 65% D
Total Return N/A 69% C- 83% B
Risk Return Profile  
Volatility (Standard Deviation) 8.38% 68% D+ 74% C
Risk Adjusted Return 100.00% 99% N/A 98% N/A
Market Capitalization 0.66B 72% C 64% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike